Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Gross Profit: 2010-2025

Historic Gross Profit for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $111.7 million.

  • Ligand Pharmaceuticals' Gross Profit rose 126.20% to $111.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.8 million, marking a year-over-year increase of 66.15%. This contributed to the annual value of $156.1 million for FY2024, which is 29.19% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Gross Profit stood at $111.7 million for Q3 2025, which was up 149.69% from $44.7 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Gross Profit high stood at $111.7 million for Q3 2025, and its period low was $24.7 million during Q2 2023.
  • In the last 3 years, Ligand Pharmaceuticals' Gross Profit had a median value of $40.0 million in 2024 and averaged $43.1 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Gross Profit slumped by 35.24% in 2022, and later surged by 126.20% in 2025.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Gross Profit stood at $44.4 million in 2021, then crashed by 35.24% to $28.8 million in 2022, then fell by 8.02% to $26.5 million in 2023, then skyrocketed by 51.08% to $40.0 million in 2024, then surged by 126.20% to $111.7 million in 2025.
  • Its Gross Profit was $111.7 million in Q3 2025, compared to $44.7 million in Q2 2025 and $40.5 million in Q1 2025.